Replies to post #195897 on Biotech Values

[DewDiligence]

OXGN—OXi4503 finally starts phase-1/2 after more than a decade in planning:

http://finance.yahoo.com/news/oxigene-announces-initiation-phase-1b-201500850.html

(Don’t ask why the “i” in OXi4503 is lower case—I have no idea.)

[DewDiligence]

OXGN +7%/AH on phase-1b data for CA4P in ovarian cancer:

http://finance.yahoo.com/news/oxigene-announces-positive-initial-data-211500084.html

OXiGENE, Inc…today announced initial data from a Phase 1b/2 study of the company's lead investigational drug, CA4P, in combination with the anti-angiogenic agent Votrient (pazopanib) in patients with advanced recurrent ovarian cancer.

"The initial results we've seen to date from the Phase 1b portion of PAZOFOS are encouraging and we expect to move into the phase 2 portion of the study in early 2016," said Professor Gordon Rustin, Director of Medical Oncology, Mount Vernon Cancer Centre and a chief investigator for the trial. "

[DewDiligence]

MATN (f/k/a OXGN) -51% on phase-2/3 failure in ovarian cancer and termination of CA4P development (after all these years):

http://investor.mateon.com/releasedetail.cfm?ReleaseID=1041745

The drug MATN will now focus on, OXI4503, has been in development for 14 years! Check the date on this post: #msg-2166339.